Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular Dysfunction

Q: What was the study purpose regarding AILVD and LVEF recovery?

To evaluate associations of neurohormonal blockers and other clinical factors with recovery of LVEF in patients with anthracycline-induced left ventricular dysfunction.

Q: How were patients included in the study?

Patients received at least one dose of anthracycline, had at least a 10% LVEF reduction or post-anthracycline LVEF <50%, and then had a follow-up LVEF measurement at least 90 days later.

Q: Which factors were independently associated with improved LVEF recovery?

Higher beta-blocker dose after anthracycline exposure and a shorter time from anthracycline start to the lowest post-anthracycline LVEF were significantly and independently associated with better LVEF recovery.

Sep 28, 2026

Uploaded by Finn

This retrospective chart review evaluated associations between neurohormonal blocking drugs and recovery of left ventricular ejection fraction (LVEF) in patients with anthracycline-induced left ventricular dysfunction (AILVD). Neurohormonal agents such as beta-blockers, ACEIs, and ARBs are recommended, yet evidence of benefit is limited. Among 104 patients, recovery was independently associated with higher beta-blocker dose after anthracycline exposure and earlier detection of post-anthracycline LVEF reduction.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages20

Reading Time50 min

AccessFree to download

Abstract

Methods

Study design and eligibility

Results

Patient characteristics and final model

Conclusions

Keywords

Introduction

Author Manuscript Author Manuscript Author Manuscript Author Manuscript | | HHS Public Access
Author manuscript
J Cardiovasc Pharmacol Ther. Author manuscript; available in PMC 2026 January 01. | | --- | --- | Published in final edited form as: J Cardiovasc Pharmacol Ther. 2025 ; 30: 10742484241304304. doi:10 . 1177/10742484241304304 . Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular Dysfunction Tyler Shugg 1,2 , Tk Nguyen2 , Xuesi Hua2 , Blair Richards3 , James Rae4 , Robert Dess5 , Daniel Perry6 , Bradley Kay7 , Salim S. Hayek6 , Monika Leja6 , Jasmine A. Luzum2 1 Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA 2 Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA 3Michigan Institute for Clinical & Health Research (MICHR), University of Michigan, Ann Arbor, MI, USA 4 Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, USA 5 Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA 6 Division of Cardiovascular Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA 7 Department of Cardiology, Yale School of Medicine, New Haven, CT, USA Abstract Background—Neurohormonal blocking drugs, like beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs), are recommended for treating anthracycline-induced left ventricular dysfunction (AILVD) . However, there is limited evidence supporting their benefit. Therefore, this study evaluated associations of neurohormonal blockers and other clinical factors with recovery of left ventricular ejection fraction (LVEF) inpatients with AILVD. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page ([https://us.sagepub.com/](https://us.sagepub.com/)[ ](https://us.sagepub.com/)[en-us/nam/open-access-at-sage](en-us/nam/open-access-at-sage)) . Jasmine A. Luzum, University of Michigan College of Pharmacy, 1100 North University Ave, Ann Arbor, MI, 48109, USA. [jluzum@med.umich.edu](jluzum@med.umich.edu). Author Contributions Data collection: TS, TN, JE, BR, BD, DP, and BK; interpretation: TS, TN, JE, XH, BR, JR, BD, DP, BK, SSH, and MJ; writing: TS, TN, JE, XH, SSH, and JAL; revision: TS, TN, JE, XH, JR, BD, DP, BK, SSH, ML, and JAL; data analysis: TN, BR, and JAL; critical review: TS, TN, JE, XH, BR, JR, BD, DP, BK, SSH, ML, and JAL; funding acquisition: ML and JAL; conceptualization: JR, ML, and JAL. Declaration of Conflicting Interests The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.A.L. is a consultant for Ariel Precision Medicine. The other authors have no conflicts of interest to disclose. Supplemental Material Supplemental material for this article is available online. Author Manuscript Author Manuscript Author Manuscript Author Manuscript Shugg et al. Page 2 Methods—This retrospective chart review assessed patients treated with at least one dose of anthracycline, then had ≥10% LVEF reduction or post-anthracycline LVEF value <50%, and then had a follow-up LVEF measurement ≥90 days later. The primary endpoint was LVEF recovery (highest follow-up LVEF-lowest LVEF post-anthracycline) . Variables from univariable tests with P < .1 were incorporated in a multiple linear regression model for independent factors significantly associa

FAQs

What was the study purpose regarding AILVD and LVEF recovery?

To evaluate associations of neurohormonal blockers and other clinical factors with recovery of LVEF in patients with anthracycline-induced left ventricular dysfunction.

How were patients included in the study?

Patients received at least one dose of anthracycline, had at least a 10% LVEF reduction or post-anthracycline LVEF <50%, and then had a follow-up LVEF measurement at least 90 days later.

Which factors were independently associated with improved LVEF recovery?

Higher beta-blocker dose after anthracycline exposure and a shorter time from anthracycline start to the lowest post-anthracycline LVEF were significantly and independently associated with better LVEF recovery.

Sep 28, 2026

Uploaded by Finn